The smaller-than-expected proportion of T1D patients on pump therapy [39] represents a selection bias, which may be explained by two factors: (i) insulin pump therapy often enables better glycaemic control, reducing the perceived need for add-on SGLT2 inhibitors; and (ii) concerns about an increased risk of DKA in pump users may discourage clinicians from prescribing SGLT2 inhibitors in this population. The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.